Leading the fight against cancer. Always focused on you.
We deliver personalized treatment you won't get anywhere else, led by a team of world-renowned doctors, specialists, and scientists.
Selwyn M. Vickers, MD, named President and CEO
Dr. Vickers, an internationally recognized cancer surgeon and researcher, will succeed Craig B. Thompson, MD, as MSK's President and CEO in September 2022.
Give today. Impact the care of tomorrow.
Your generosity helps support groundbreaking research, world-class care for patients and their families, and vital education programs to train the next generation of cancer experts.
Changing how the world treats cancer through research
Our scientists pursue every aspect of cancer research — from exploring the fundamental biology of genes and cells, to developing immune-based treatments for cancer, uncovering the causes of metastasis, and more.
Let's get started
Trastuzumab Deruxtecan (T-DXd) for Treating HER2-Low Breast Cancer Shows Promise
Patients with HER2-low breast cancer may have a new treatment option, the drug trastuzumab deruxtecan (T-DXd), according to a study led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
Podcast | Cancer Straight Talk
Breakthrough Rectal Cancer Drug Trial: What It Means For You
A recent clinical trial for rectal cancer headed up by Memorial Sloan Kettering has grabbed the attention of medical oncologists and cancer scientists around the world. Like a miracle, in a subset of patients with the right genetic makeup, an IV infusion of an immunotherapy caused a complete remission.